Disclosed are means, methods, and compositions of matter useful for treatment of autoimmunity comprising exposing patient T cells fibroblasts possessing tolerogenic properties. In one embodiment peripheral blood mononuclear cells are cultured in the presence of CD73 selected fibroblasts alone or in the presence of interleukin-2, and/or IL-7, and/or TGF-beta, and/or PGE-2 for a period of time sufficient to endow tolerogenic properties. Said tolerogenic properties include ability to suppress adaptive or innate immune responses. In another embodiment the disclosure provides methods of generating antigen specific immune regulatory cells by culture of T cells together with fibroblasts in the presence of antigen to which specific immune regulation is desired.

This document provides methods and materials for expanding tumor infiltrating γδ T cells (e.g., tumor infiltrating γδ T cells) in culture. For example, methods and materials for expanding large numbers of tumor infiltrating γδ T cells (e.g., tumor infiltrating γδ T cells that are predominantly Vδ1.sup.+) from tissue obtained from a mammal having cancer (e.g., a tumor sample), an autoimmune condition, or an infection are provided. Populations of such tumor infiltrating γδ T cells and methods and materials for using such tumor infiltrating γδ T cells and/or such populations to treat cancer within a mammal (e.g., a human) also are provided.

The present invention provides methods of expanding γδ T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded γδ T cells and methods of using the expanded γδ T cells (e.g., apart of an adoptive T cell therapy).

In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.

The present invention provides modified monocytes, modified macrophages, pharmaceutical compositions comprising the modified monocytes or modified macrophages described herein and at least one pharmaceutically acceptable carrier or excipient. Uses of the modified monocytes or the modified macrophages for the treatment of musculoskeletal diseases and inducing cartilage formation are provided. Also disclosed herein are in vitro culture methods for generating the modified macrophages.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present invention provides methods compositions and methods of preparing autologous (or allogeneic) B cells that secrete a monoclonal of interest useful in immunotherapy or B cells with an altered function.

The present invention relates to the preparation and use in recipients of CAR-T cell-derived effector cells which are modified to limit their proliferation within the recipient. This is accomplished through the introduction of adducts into the nucleic acids of CAR-T cell-derived effector cells following expansion in vitro to provide expanded and activated CAR-T cell-derived effector cells that retain immunologic function, including the expression of one ore more cytokines.

Provided is a cell culture substrate for trait induction control of a macrophage, which has a pattern of unevenness on a surface to which a cell adheres, the width of the unevenness being 50 nm or more and less than 1,000 nm.

A trait induction method of undifferentiated cells is provided, including: culturing undifferentiated cells on abase material which has an uneven pattern on the surface to which the cells adhere and of which the width of the unevenness is 1 nm to 1,000 nm.